In VivoCompleting an initial public offering ought to be a big step in company development. It is a departure from a cosseted, insulated environment of unique technical approaches and regulatory progress and
ScripScrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent transactions. Deal Watch is supported by deal in
ScripRitter Pharmaceuticals, Inc. has appointed AnnKatrin Petersen-Jappelli chief medical officer (CMO). Petersen-Jappelli, who is currently on the board of Salgomed Inc., brings 25 years of drug developme
ScripInfection with the hepatitis C virus (HCV) represents an important healthcare problem worldwide. Current estimates suggest that globally about 170 million people, representing approximately 3% of the